| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| Lifecodes Corporation |
| 550 West Avenue, Stamford, CT 06902 * (203) 328-9500 |
| The company is a leading provider of DNA testing services and related products for human paternity and forensic identification and for genetic typing of potential donors and recipients of bone marrow and organ transplants. |
| Manager | Tier | Phone |
| Volpe Brown Whelan & Company | Lead Manager | (415) 274-4463 |
| Advest, Inc. | Co-manager | (860) 509-2177 |
| Vector Securities International, Inc. | Co-manager | (800) 546-1231 |
| NASNTL: | LFCD | Service: | SIC 8071 | |
| Type of Shares: | Common Shares | Filing Date: | 7/17/98 | |
| U.S. Shares Filed: | 3,200,000 | Filing Range: | $10.00 - $12.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $35,200,000 | |
| Primary Shares: | 2,900,000 | Expenses: | $1,200,000 | |
| Secondary Shares: | 300,000 | Post-IPO Shares: | 6,560,857 | |
| Employees: | 305 |
| Issuer's Law Firm: | Wiggin & Dana |
| Bank's Law Firm: | Testa, Hurwitz & Thibeault |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
| Auditor: | Deloitte & Touche |
Dollar amounts in U.S. millions except for per share data | |||||
| 6 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 9/30/97 | 3/31/98 | 3/31/97 | 3/31/98 | ||
| Revenue: | $15.07 | $10.25 | $5.71 | Assets: | $10.97 |
| Net Income: | $0.39 | $0.43 | -$0.10 | Curr Assets: | $5.43 |
| EPS: | $0.18 | $0.19 | -$0.05 | Liabilities: | $8.62 |
| Prior EPS: | -$0.32 | $0.42 | $0.06 | Curr Liab: | $4.52 |
| Cash Flow/Oper: | $1.14 | $1.06 | -$0.03 | Equity: | $2.36 |
| Cash Flow/Fin: | -$0.44 | -$1.40 | -$0.13 | Cash: | $0.73 |
| Cash Flow/Inv: | -$0.84 | Working Cap: | $0.92 | ||
| Use of Proceeds |
| The proceeds from the proposed offering will be used for payment of the cash portion of the purchase price of the GeneScreen Acquisition, repayment of indebtedness, and for general corporate purposes including working capital and possible future acquisitions. |